Toragen, Inc., receives grant to conduct studies to explore application of TGN-S15 for premalignant lesions at earliest stages November 3, 2025 Categories: Health Care Tags: Toragen
Toragen, Inc. announces $12 million convertible note financing and expansion of board of directors October 7, 2025 Categories: Health Care Tags: Toragen
Toragen, Inc. announced positive safety data update from Cohort 2 and the initiation of its dose expansion of its Phase 1 trial in patients with human papillomavirus-induced cancer December 18, 2023 Categories: Health Care Tags: Toragen
Toragen, Inc. announced positive safety update from Cohort 1 of its Phase 1 Trial in patients with human Papillomavirus-induced cancer November 7, 2023 Categories: Health Care Tags: Toragen
Toragen, Inc. announces FDA acceptance of IND application for TGN-S11 for the treatment of HPV-induced cancers March 6, 2023 Categories: Health Care Tags: Toragen
Toragen, Inc. announces appointment of Chief Scientific Officer February 9, 2023 Categories: Health Care Tags: Toragen
Toragen, Inc. announces appointment of Dr. Sandra Coufal, M.D. as CEO February 11, 2022 Categories: Health Care Tags: Toragen
